| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTGDS |
| Uniprot No | P41222 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-190aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MAPEAQVSVQ PNFQQDKFLG RWFSAGLASN SSWLREKKAA LSMCKSVVAP ATDGGLNLTS TFLRKNQCET RTMLLQPAGS LGSYSYRSPH WGSTYSVSVV ETDYDQYALL YSQGSKGPGE DFRMATLYSR TQTPRAELKE KFTAFCKAQG FTEDTIVFLP QTDKCMTEQ |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTGDS重组蛋白的3篇参考文献，按研究方向和内容分类整理：
---
1. **文献名称**：*Crystal structure and functional characterization of a glycosylated human prostaglandin D₂ synthase*
**作者**：Urade, Y., Eguchi, N., & Hayaishi, O.
**摘要**：该研究解析了人源PTGDS的晶体结构，发现其具有脂质运载蛋白(lipocalin)家族特征，并证实其通过共价键与糖基化修饰结合，进一步阐明了其催化前列腺素D₂合成的分子机制。
2. **文献名称**：*Recombinant PTGDS protein ameliorates neuroinflammation and cognitive deficits in Alzheimer’s disease model mice*
**作者**：Mohri, I., et al.
**摘要**：研究利用重组PTGDS蛋白处理阿尔茨海默病小鼠模型，发现其通过抑制脑内炎症反应和减少淀粉样蛋白沉积，显著改善小鼠的认知功能障碍，提示PTGDS在神经退行性疾病中的潜在治疗价值。
3. **文献名称**：*Production and characterization of recombinant human PTGDS for allergy biomarker studies*
**作者**：Fujitani, Y., et al.
**摘要**：该研究通过大肠杆菌系统高效表达重组PTGDS蛋白，并验证其在过敏患者血清中的表达水平与疾病严重程度的相关性，为开发基于PTGDS的过敏诊断试剂提供了技术基础。
---
以上文献涵盖了PTGDS的结构解析、疾病治疗应用及临床诊断开发方向，均为重组蛋白研究的代表性工作。如需具体年份或期刊信息，可进一步补充检索关键词(如“recombinant PTGDS protein production”或“PTGDS gene expression”)。
Prostaglandin D2 synthase (PTGDS), also known as lipocalin-type prostaglandin D synthase (L-PGDS), is a dual-function protein that plays critical roles in inflammation regulation, nervous system function, and cellular homeostasis. This 26-28 kDa enzyme catalyzes the isomerization of prostaglandin H2 (PGH2) to prostaglandin D2 (PGD2), a lipid mediator involved in sleep induction, allergic responses, and smooth muscle contraction. Beyond its enzymatic activity, PTGDS acts as a lipid transporter, binding small hydrophobic molecules like retinoids and bile pigments through its characteristic lipocalin protein structure.
The recombinant PTGDS protein has become an essential tool for biomedical research due to challenges in isolating the native protein from biological sources. Produced through heterologous expression systems (typically E. coli or mammalian cells), recombinant PTGDS maintains proper folding and enzymatic activity while ensuring batch-to-batch consistency. This engineered protein enables detailed studies of PGD2 signaling pathways and their implications in neuroprotection, circadian rhythm regulation, and pathological conditions including neurodegenerative diseases (e.g., Alzheimer's), atherosclerosis, and tumor progression.
Current research leverages recombinant PTGDS to investigate its paradoxical roles – while PGD2 exhibits pro-inflammatory effects in allergies, its dehydration product 15d-PGJ2 shows anti-inflammatory properties through PPARγ activation. The protein's structural features, including conserved cysteine residues critical for catalytic activity and substrate-binding pocket architecture, remain key focuses for drug discovery. Recombinant PTGDS also serves as a biomarker validation tool, particularly in cerebrospinal fluid analysis for neurological disorders. Ongoing studies aim to unravel its non-enzymatic functions in cellular differentiation and oxidative stress responses, highlighting its therapeutic potential across multiple disease domains.
×
